Highlights and insights into soligenix

Dr. chris schaber discusses soligenix hybryte(tm) and thermostabilized vaccinesnew york, new york--(newsfile corp. - october 13, 2021) - pcg digital -- in a recent interview with kristen kluska, a biotechnology analyst at cantor, dr. chris schaber, president and ceo of soligenix (nasdaq: sngx), spoke about the latest developments with their synthetic hypericin topical treatment hybryte™ and the company's ongoing research and development of thermostabilized vaccine candidates for filoviruses and covid-19. the interview took place at the cantor fitzgerald global health care conference,...
SNGX Ratings Summary
SNGX Quant Ranking